antibody

HLA Class 2 Antigen DR11 (R0.82)

MBS603993

0.1 mL

535 USD

monoclonal

mouse

nonconjugated

[4i131]

Antibody

HLA Class 2 Antigen DR11 (R0.82)

[HLA Class 2 Antigen DR11]

[Anti -HLA Class 2 Antigen DR11 (R0.82)]

[human leucocyte antigen A alpha chain; Leucocyte antigen A alpha chain; HLA class I histocompatibility antigen, A-1 alpha chain; antigen presenting molecule; leukocyte antigen class I-A; MHC class I antigen HLA-A heavy chain; major histocompatibility complex, class I, A]

[HLA-A; HLA-A; HLAA]

Q9UQU0_HUMAN

Monoclonal

IgG

[4i131]

Mouse

Human

Recognizes HLA Class 2 Antigen-DR11. Specificity was determined at a 1:10 dilution by the Microcytotoxicity test under standard NIH conditions.

Ascites

Supplied as a lyophilized powder from PBS, 1% BSA. Reconstitute with 100ul sterile dH2O to make a 10X stock solution.

Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

This antibody has not been tested in methodologies other than Microcytoxicity Test. Potential applications include Flow Cytometry, Cell typing, Tissue Staining and Chimerism Studies.

Recommended Dilution:. Cytotoxicity: Add 0.9ml of 1% BSA in PBS to 100ul of 10X working dilution. Optimal dilutions to be determined by the researcher.

Grade: Ascites. Source: Ascites fluid. Cytotoxicity: Expected Results: . Cell death will occur in any test well where the HLA cell surface antigen is recognized by its matched anti-HLA antibody. Live lymphocytes indicate a negative reaction. Dead lymphocytes indicate a positive reaction. Limitations: . Cell isolation difficulties, contamination of the lymphocyte preparation with red blood cells, monocytes, platelets or granulocytes, cell concentrations outside acceptable levels, bacterial contamination and/or change in pH of antisera may cause erroneous results.

mportant Note for small quantities: Liquids: Apparent volume may be reduced due to evaporation. Add buffer to nominal volume and dilute per instructions. During shipment, small volume products may have adhered to the interior surface of the vial. To recover the maximum amount of product, centrifuge the vial lightly for 1-3 minutes and use a fine tipped pipette for removal. To recover the maximum amount of total product, wash the vial with your assay buffer/diluent. Small volumes of product (less than or equal to 25ul) should be diluted for complete product recovery. Powders: During shipment, small volume products may have adhered to the interior surface of the vial. To recover the maximum amount of product, centrifuge the vial lightly. To recover the maximum amount of total product, wash the vial with your assay buffer/diluent. Small volumes ~25-50ul should be diluted for complete product recovery.

Antibodies; Abs to HLA

Cell death will occur in any test well where the HLA cell surface antigen is recognized by its matched anti-HLA antibody. Live lymphocytes indicate a negative reaction. Dead lymphocytes indicate a positive reaction.

4699894

CAB41636.1

Q9UQU0

Adaptive Immune System Pathway (366160); Allograft Rejection Pathway (83123); Allograft Rejection Pathway (535); Antigen Presentation: Folding, Assembly And Peptide Loading Of Class I MHC Pathway (366163); Antigen Processing And Presentation Pathway (83074); Antigen Processing And Presentation Pathway (485); Antigen Processing-Cross Presentation Pathway (477122); Autoimmune Thyroid Disease Pathway (83121); Autoimmune Thyroid Disease Pathway (533); Cell Adhesion Molecules (CAMs) Pathway (83069)

HLA-A belongs to the HLA class I heavy chain paralogues. This class I molecule is a heterodimer consisting of a heavy chain and a light chain (beta-2 microglobulin). The heavy chain is anchored in the membrane. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. They are expressed in nearly all cells. The heavy chain is approximately 45 kDa and its gene contains 8 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the alpha1 and alpha2 domains, which both bind the peptide, exon 4 encodes the alpha3 domain, exon 5 encodes the transmembrane region, and exons 6 and 7 encode the cytoplasmic tail. Polymorphisms within exon 2 and exon 3 are responsible for the peptide binding specificity of each class one molecule. Typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. Hundreds of HLA-A alleles have been described. [provided by RefSeq, Jul 2008]

HLAA: Involved in the presentation of foreign antigens to the immune system. Belongs to the MHC class I family. Protein type: Immunoglobulin superfamily; Membrane protein, integral. Chromosomal Location of Human Ortholog: 6p21.3. Cellular Component: Golgi membrane; Golgi apparatus; phagocytic vesicle membrane; cell surface; membrane; early endosome membrane; integral to plasma membrane; endoplasmic reticulum; plasma membrane; MHC class I protein complex; Golgi medial cisterna. Molecular Function: protein binding; peptide antigen binding; beta-2-microglobulin binding; T cell receptor binding; TAP binding; receptor binding. Biological Process: regulation of immune response; viral reproduction; detection of bacterium; positive regulation of T cell mediated cytotoxicity; cytokine and chemokine mediated signaling pathway; antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent; antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; regulation of defense response to virus by virus; protection from natural killer cell mediated cytotoxicity; positive regulation of interferon-gamma production; antigen processing and presentation of peptide antigen via MHC class I; antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent; antigen processing and presentation of exogenous peptide antigen via MHC class I; immune response. Disease: Severe Cutaneous Adverse Reaction, Susceptibility To

0.1 mL

535 USD